The DOI matches its Crossref record; 111 of the 122 references it cites were found in a registry or an index; none of the 207 sources its claims cite is checked for support yet.
Diagnosis and Treatment of Subclinical Hypercortisolism
Open accessAbstract
Context: Subclinical hypercortisolism (SH) is a condition of biochemical cortisol excess without the classical signs or symptoms of overt hypercortisolism. It is thought to be present in the 5–30% of patients with incidentally discovered adrenal mass (adrenal incidentalomas), which in turn are found in 4–7% of the adult population. Therefore, SH has been suggested to be present in 0.2–2.0% of the adult population. Some studies suggested that this condition is present in 1–10% of patients with diabetes or established osteoporosis. The present manuscript reviews the literature on diagnostic procedures and the metabolic effect of the recovery from SH. Evidence Acquisition: A PubMed search was used to identify the available studies. The most relevant studies from 1992 to November 2010 have been included in the review. Evidence Synthesis: The available data suggest that SH may be associated with chronic complications, such as hypertension, diabetes mellitus, overweight/obesity, and osteoporosis. The available intervention studies suggest that the recovery from SH may lead to the improvement of hypertension and diabetes mellitus. A retrospective study suggests that this beneficial effect could be predicted before surgery. Conclusions: SH is suggested to be associated with some chronic complications of overt cortisol excess. Recovery from this condition seems to improve these complications. However, a large, prospective, randomized study is needed to confirm this hypothesis and to establish the best diagnostic approach to identify patients with adrenal incidentalomas who can benefit from surgery.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review summarizes the diagnosis, prevalence, and management of subclinical hypercortisolism (SH), defined as biochemical cortisol excess without classical signs or symptoms of overt hypercortisolism. It concludes that no consensus or gold standard exists for diagnosis, that the DST-UFC-ACTH combination is the best available compromise, and that surgery may improve metabolic complications but evidence remains limited.
Key findings
- SH is estimated to be present in 5–30% of patients with adrenal incidentalomas (AI); because AI are found in 4–7% of adults, SH may be present in 0.2–2.0% of the adult population, and in 1–10% of patients with diabetes or established osteoporosis.
- No single HPA-axis parameter has adequate sensitivity and specificity. In one scintigraphy-validated study, the 1-mg DST cutoff of 3.0 μg/dl showed the best compromise (sensitivity 63%, specificity 75%); in 231 AI patients, the DST-UFC-ACTH combination criterion had sensitivity 61.9%, specificity 77.1%, and accuracy 75.8% for predicting a cluster of complications.
- Prevalence in at-risk groups varied: 10.8% in 294 type 2 diabetic inpatients; 4.8% in osteoporosis and 10.8% in osteoporosis with vertebral fractures. SH appears more commonly of adrenal than pituitary origin.
- In the only prospective randomized study cited (23 surgically treated, 22 conservatively treated), surgery improved hypertension, diabetes, obesity, and dyslipidemia in 66.7%, 62.5%, 50%, and 37.5% of cases, respectively; conservative management worsened hypertension, diabetes, and dyslipidemia in 80%, 33.3%, and 20%.
Methods
- Narrative clinical review of the literature on diagnostic procedures and the metabolic effects of recovery from SH.
- Synthesizes studies of patients with adrenal incidentalomas and at-risk populations (diabetes, osteoporosis), including diagnostic accuracy studies and surgical versus conservative treatment/follow-up studies; tables summarize HPA-axis alterations, diagnostic accuracy, prevalence, and outcomes.
- Main analysis is qualitative synthesis; no new primary data or meta-analysis are presented.
Limitations
- The paper states there is no consensus on clinical or biochemical criteria for SH, no clinical gold standard, and that cortisol secretion is a continuum and highly variable; ACTH and 24-h UFC reliability is low, comorbidities and medications affect the DST, and salivary cortisol methods are not standardized.
- The paper states that no large prospective randomized trial has compared surgical versus conservative treatment, available studies are small and often retrospective or nonrandomized, and data on hard endpoints and cost-effectiveness are lacking.
- Evident from the text: as a single-author narrative review, it draws on heterogeneous studies with differing cutoffs, assays, and outcome definitions, which limits comparability across findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 207 cited sources checked · 0 supported · 0 flagged
In the paper
“In patients with 1-mg DST between these values, the presence of MSeC greater than 4.0 mg/dl (110 nmol/liter) or ACTH less than 10.0 pg/ml (2.2 pmol/ liter) combined with the presence of at least two metabolic complications before surgery had a 76% accuracy in predicting improvement.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Looking to the above-mentioned retrospective data on 55 surgically treated patients with AI (60), 1-mg DST greater than 5 g/dl (138 nmol/liter) and less than 2 g/dl (55 nmol/liter) had the best specificity and sensitivity (96.9 and 91.3%, respectively) for identifying patients that may improve after surgery.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Using the protocol illustrated in the study, in more than 80% of cases the improvement after surgery was correctly predicted before surgery (60).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“the progression toward overt clinical hypercortisolism is very rare (11)(12)(13).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Abstract
What the sources say
- Not checked yetcites (11)(12)(13)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“the glucocorticoid sensitivity may be different among the different individuals and among the different tissues in the same individual, due also to polymorphisms of both glucocorticoid receptor (25)(26)(27)(28) and 11-hydroxysteroid-dehydrogenase type 1 genes (29,30).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Pitfalls in the diagnosis of SH
What the sources say
- Not checked yetcites (25)(26)(27)(28)
- Not checked yetcites [29] Tomlinson, 2004, 11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response., Endocr Rev source
- Not checked yetcites [30] Hwang, 2009, HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without clinically apparent hypercortisolemia., Bone source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, diagnosing SH by arbitrary cutoffs of indexes of cortisol secretion leads to unavoidable mistakes in classifying some patients.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Pitfalls in the diagnosis of SH
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Because AI are thought to be present in up to 4 -7% of adults (6 -11)”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Abstract
What the sources say
- Not checked yetcites [6] Griffing, 1994, Editorial A-I-D-S: the new endocrine epidemic., J Clin Endocrinol Metab
- Not checked yetcites [7] Glazer, 1982, Nonfunctioning adrenal masses: incidental discovery on computed tomography., AJR Am J Roentgenol source
- Not checked yetcites [8] Bovio, 2006, Prevalence of adrenal incidentaloma in a contemporary computerized tomography series., J Endocrinol Invest source
- Not checked yetcites [9] Mantero, 2000, A survey on adrenal incidentaloma in Italy., J Clin Endocrinol Metab
- Not checked yetcites [10] Chidiac, 1997, Incidentaloma. A disease of modern technology., Endocrinol Metab Clin North Am source
- Not checked yetcites [11] Young, 2000, Management approaches to adrenal incidentalomas: a view from Rochester, Minnesota., Endocrinol Metab Clin North Am source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“the prevalence of SH in this population may be estimated to be between 0.2 and 2.0% (2).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Abstract
What the sources say
- Not checked yetcites [2] Reincke, 2000, Subclinical Cushing's syndrome., Endocrinol Metab Clin North Am source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In more than 25% of AI subjects, the lack of cortisol suppression after 1-or 3-mg overnight DST or 2-d low-dose DST (LDDST) (19,34,41,44,46,48,53,55,56,60,61)”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [19] Chiodini, 2004, Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effect of subclinical hypercortisolism and gonadal status., J Clin Endocrinol Metab source
- Not checked yetcites [34] Reincke, 1992, Preclinical Cushing's syndrome in adrenal incidentalomas: comparison with adrenal Cushing's syndrome., J Clin Endocrinol Metab
- Not checked yetcites [41] Tsagarakis, 1998, Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas., Clin Endocrinol (Oxf) source
- Not checked yetcites [44] Tanabe, 2001, Autonomy of cortisol secretion in clinically silent adrenal incidentaloma., Horm Metab Res source
- Not checked yetcites [46] Midorikawa, 2001, The improvement of insulin resistance in patients with adrenal incidentalomas by surgical resection., Clin Endocrinol (Oxf) source
- Not checked yetcites [48] Valli, 2001, Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [53] Chiodini, 2002, Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism., J Clin Endocrinol Metab source
- Not checked yetcites [55] Hadjidakis, 2003, Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?, Clin Endocrinol (Oxf) source
- Not checked yetcites [56] Katabami, 2005, Discrepancies in results of low- and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome., Endocr J source
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“there is no consensus yet on the clinical and/or biochemical criteria to diagnose this condition.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Pitfalls in the diagnosis of SH
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 43
- Probably not a substantial claim. 11
In the paper
“Moreover, after excluding MSeC, all combinations of the remaining parameters did not show enough reliability for predicting hypocortisolism after surgery, and conversely, the normality of all parameters of HPA axis activity before surgery could not rule out with 100% probability the appearance of postsurgical adrenal insufficiency.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [58] Eller-Vainicher, 2010, Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?, Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Also in this study, lowering the cutoff of 1-mg DST was demonstrated to lead to a reduction in specificity (from 85.7 to 23.8%) and an increase in sensitivity (from 33.3 to 79.5%).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [58] Eller-Vainicher, 2010, Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?, Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“We found that the simultaneous presence of elevated UFC and MSeC levels [Ͼ5.4 g/dl (149 nmol/liter)] before surgery had a 100% specificity for predicting postsurgical hypocortisolism, but at the expense of a 30.8% sensitivity.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [58] Eller-Vainicher, 2010, Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?, Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The DST-UFC-ACTH combination criterion was confirmed to be useful because it showed the best accuracy in predicting improvement (sensitivity, 65.2%; specificity, 68.8%) in surgically treated patients and worsening of the endpoints (sensitivity, 55.6%; specificity, 82.9%), in the conservatively treated subjects.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Some studies suggested that this condition is present in 1-10% of patients with diabetes or established osteoporosis.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Abstract
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“particularly in AI patients, cortisol secretion is a continuum from completely normal to clearly increased levels, and it is highly variable in the same individual (3,22).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Pitfalls in the diagnosis of SH
What the sources say
- Not checked yetcites [3] Grumbach, 2003, Management of the clinically inapparent adrenal masses (“incidentaloma”)., Ann Intern Med source
- Not checked yetcites [22] Terzolo, 2005, Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The National Institutes of Health State-of-the-Science Conference (64) and the American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of AI (65) recommend the cutoff of 5 g/dl (138 nmol/liter) as the normal level of cortisol suppression in patients with suspected SH.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [64] 2002, NIH State-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”)., 2002 NIH Consensus and State-of-the-Science Statements
- Not checked yetcites [65] Zeiger, 2009, American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas., Endocr Pract source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Even if midnight serum cortisol (MSeC) has been shown to be a promising tool for diagnosing SH (22), its use is limited by the need of the hospital admission for the cumbersome procedure, and it could be used as a confirmative test in selected patients (60).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [22] Terzolo, 2005, Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma., Eur J Endocrinol source
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Several studies (19,21,32,34,38,39,44,46,49,53,60,61,67) and recently the French Society for Endocrinology (68), however, have proposed a lower cutoff to increase sensitivity.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [19] Chiodini, 2004, Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effect of subclinical hypercortisolism and gonadal status., J Clin Endocrinol Metab source
- Not checked yetcites [21] Chiodini, 2009, Bone mineral density, prevalence of vertebral fractures and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian Multicenter Study., J Clin Endocrinol Metab source
- Not checked yetcites [32] Masserini, 2009, The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [34] Reincke, 1992, Preclinical Cushing's syndrome in adrenal incidentalomas: comparison with adrenal Cushing's syndrome., J Clin Endocrinol Metab
- Not checked yetcites [38] Bardet, 1996, 131I-6-b-Iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of adrenocortical incidentalomas., Clin Endocrinol (Oxf) source
- Not checked yetcites [39] Bondanelli, 1997, Evaluation of hormonal function in a series of incidentally discovered adrenal masses., Metabolism source
- Not checked yetcites [44] Tanabe, 2001, Autonomy of cortisol secretion in clinically silent adrenal incidentaloma., Horm Metab Res source
- Not checked yetcites [46] Midorikawa, 2001, The improvement of insulin resistance in patients with adrenal incidentalomas by surgical resection., Clin Endocrinol (Oxf) source
- Not checked yetcites [49] Chiodini, 2001, Bone loss rate in adrenal incidentalomas: a longitudinal study., J Clin Endocrinol Metab source
- Not checked yetcites [53] Chiodini, 2002, Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism., J Clin Endocrinol Metab source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Therefore, UFC should not be considered an adequate screening test for SH and should be used in combination with other tests or in specific populations (1,14).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Thus, reducing the cutoff of 1-mg DST leads to a decrease in specificity and, therefore, to more false diagnosis of SH (65).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [65] Zeiger, 2009, American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas., Endocr Pract source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The reason to screen for SH with a higher cutoff than that recommended for overt cortisol excess [1.8 g/dl (50 nmol/liter)] (66) is that in patients without signs or symptoms suggestive of hypercortisolism, the a priori possibility of having SH is estimated to be lower than that of a false-positive result (1).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [1] Terzolo, 2005, Subclinical Cushing's syndrome in adrenal incidentalomas., Endocrinol Metab Clin North Am source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, this test should not be used for diagnosing SH until further studies and a standardization of the laboratory methods are available.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Some authors found a low sensitivity of MSaC in identifying SH (31,32), whereas others showed that subjects with either consistent or frequent elevations of this parameter may actually have SH (69).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [31] Nunes, 2009, Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients., J Clin Endocrinol Metab source
- Not checked yetcites [32] Masserini, 2009, The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [69] Kidambi, 2007, Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome., Eur J Endocrinol source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Similarly, LDDST has been used to diagnose SH (18,40,41,55) without advantages, with the exception of patients affected with alcoholism, psychiatric disorders, and diabetes in whom this test may be more accurate (1,14,66).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [18] Rossi, 2000, Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features., J Clin Endocrinol Metab
- Not checked yetcites [40] Kasperlik-Zeluska, 1997, Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients., Clin Endocrinol (Oxf) source
- Not checked yetcites [41] Tsagarakis, 1998, Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas., Clin Endocrinol (Oxf) source
- Not checked yetcites [55] Hadjidakis, 2003, Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?, Clin Endocrinol (Oxf) source
- Not checked yetcites [1] Terzolo, 2005, Subclinical Cushing's syndrome in adrenal incidentalomas., Endocrinol Metab Clin North Am source
- Not checked yetcites [14] Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline., J Clin Endocrinol Metab source
- Not checked yetcites [66] Arnaldi, 2003, Diagnosis and complications of Cushing's syndrome: a consensus statement., J Clin Endocrinol Metab source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Because the increase in sensitivity is accompanied by the decrease in specificity with the lowering of the 1-mg DST cutoff and vice versa, the combination of different parameters of HPA axis activity has been proposed to increase specificity without affecting sensitivity.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“The main criticism to this approach for diagnosing SH is that postsurgical hypocortisolism reflects only the pituitary sensi- tivity to cortisol excess and not that at the peripheral tissues (25)(26)(27)(28)(29)(30).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites (25)(26)(27)(28)(29)(30)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“In particular, ACTH levels above 20 pg/ml (4.4 pmol/liter) or below 10 pg/ml (2.2 pmol/liter) suggest an ACTH-dependent or -independent cause of SH, respectively (66).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [66] Arnaldi, 2003, Diagnosis and complications of Cushing's syndrome: a consensus statement., J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, if the lowest cutoffs were used [1.8 and 2.2 g/dl (50 and 60.6 nmol/liter), respectively], specificity decreased to 67-72%, whereas sensitivity increased to 75-100% (48 -62, 64 -67).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [48] Valli, 2001, Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [49] Chiodini, 2001, Bone loss rate in adrenal incidentalomas: a longitudinal study., J Clin Endocrinol Metab source
- Not checked yetcites [50] Barzon, 2002, Development of overt Cushing's syndrome in patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [51] Bülow, 2002, Adrenal incidentaloma—experience of a standardized diagnostic programme in the Swedish prospective study., J Intern Med source
- Not checked yetcites [52] Libè, 2002, Long-term follow-up study of patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [53] Chiodini, 2002, Bone involvement in eugonadal male patients with adrenal incidentaloma and subclinical hypercortisolism., J Clin Endocrinol Metab source
- Not checked yetcites [54] Emral, 2003, Prevalence of subclinical Cushing's syndrome in 70 patients with adrenal incidentalomas: clinical, biochemical and surgical outcomes., Endocr J source
- Not checked yetcites [55] Hadjidakis, 2003, Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas?, Clin Endocrinol (Oxf) source
- Not checked yetcites [56] Katabami, 2005, Discrepancies in results of low- and high-dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome., Endocr J source
- Not checked yetcites [57] Toniato, 2009, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study., Ann Surg source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, the use of the DST-UFC-ACTH combination criterion is limited to the diagnosis of SH of adrenal origin because ACTH levels are useless in patients with suspected ACTH-dependent SH.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The occurrence of hypocortisolism after the removal of an adrenal adenoma has been proposed as the gold standard for diagnosing SH (58).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [58] Eller-Vainicher, 2010, Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?, Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Using the highest cutoff [5 g/dl (138 nmol/liter)], 1-mg DST was confirmed to have good specificity (83-100%) but low sensitivity (44 -58%).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [48] Valli, 2001, Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [67] Barzon, 2001, Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The limit of this approach is that these complications (i.e.osteoporosis, diabetes mellitus, and hypertension) are not specific for cortisol excess, being highly prevalent in the general population.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a seminal paper, Terzolo et al. (42) proposed the use of different combinations of several different parameters (i.e.high UFC levels, cortisol levels after 1-mg DST, high average daily serum cortisol, altered circadian cortisol rhythm, low basal ACTH levels, or blunted ACTH response to CRH) to screen for SH and the terms “definitive SH,” “probable SH,” and “possible SH”.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Alterations of HPA axis activity parameters in patients with AI
What the sources say
- Not checked yetcites [42] Terzolo, 1998, Subclinical Cushing's syndrome in adrenal incidentaloma., Clin Endocrinol (Oxf) source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overall, in these studies, the different parameters showed a good specificity (90 -98%, using 1-mg DST) but, generally, a poor sensitivity (41-86% using ACTH levels).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [9] Mantero, 2000, A survey on adrenal incidentaloma in Italy., J Clin Endocrinol Metab
- Not checked yetcites [31] Nunes, 2009, Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients., J Clin Endocrinol Metab source
- Not checked yetcites [32] Masserini, 2009, The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [52] Libè, 2002, Long-term follow-up study of patients with adrenal incidentalomas., Eur J Endocrinol source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“A few studies (summarized in Table 2) evaluated the sensitivity and specificity of the different HPA axis parameters or combination of parameters for diagnosing SH.The difficulty in performing such studies is due to the lack of a clinical, biochemical, or functional parameter that can be used as the gold standard.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is known that diabetes mellitus and osteoporosis are frequently found in patients with cortisol excess.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The altered circadian rhythm, evaluated by either MSaC or MSeC, and UFC levels were not found to be sensitive enough for diagnosing SH (31,32).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [31] Nunes, 2009, Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in hospitalized and ambulatory patients., J Clin Endocrinol Metab source
- Not checked yetcites [32] Masserini, 2009, The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas., Eur J Endocrinol source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This study confirmed the low sensitivity and specificity of 1-mg DST when the high or low cutoff, respectively, is used and the low accuracy of the reduced ACTH and increased UFC level, when used as single criterion (59).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [59] Morelli, 2010, Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects., Clin Endocrinol (Oxf) source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, to date, the DST-UFC-ACTH combination criterion seems the best compromise to diagnose SH because it has been validated on a clinical basis (32,59,60).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Diagnostic accuracy of the different approaches for diagnosing SH
What the sources say
- Not checked yetcites [32] Masserini, 2009, The limited role of midnight salivary cortisol in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentalomas., Eur J Endocrinol source
- Not checked yetcites [59] Morelli, 2010, Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects., Clin Endocrinol (Oxf) source
- Not checked yetcites [60] Eller-Vainicher, 2010, Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma., Eur J Endocrinol source
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Because in past years several studies have shown that SH may also be associated with a high risk of osteoporotic fractures and metabolic consequences (15)(16)(17)(18)(19)(20)(21)(22)”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites (15)(16)(17)(18)(19)(20)(21)(22)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Importantly, the criteria for defining an improvement of the possible complications of SH have been different among the different studies and were not always reported.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“The only available prospective randomized study found in 23 surgically treated subjects improvement of hypertension, diabetes, obesity, and dyslipidemia in 66.7, 62.5, 50, and 37.5% of cases, respectively (57).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [57] Toniato, 2009, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study., Ann Surg source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Rossi et al. (18) found that blood pressure and diabetes improved in 100 and 60% of five surgically treated SH patients, respectively, whereas no changes were seen in seven conservatively treated SH subjects.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [18] Rossi, 2000, Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features., J Clin Endocrinol Metab
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a larger study of a similar population using 1-mg DST as a screening test with a lower and, therefore, more sensitive cutoff, SH was ascertained in four (three of pituitary and one of adrenal origin) of 200 diabetic patients studied (2.0% prevalence) (82).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites [82] Catargi, 2003, Occult Cushing's syndrome in type-2 diabetes., J Clin Endocrinol Metab source
Strength:plain· not yet calibratedn = 4Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“On the contrary, in 22 conservatively treated patients, hypertension, diabetes, and dyslipidemia worsened in 80, 33.3, and 20% of cases (57).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [57] Toniato, 2009, Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study., Ann Surg source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A subsequent study from our group on more than 200 patients using the same screening test showed that SH was present in 4.8% of patients with osteoporosis and 10.8% of patients with osteoporosis and vertebral fractures.In this study, SH was of adrenal and pituitary origin in 4.1 and 0.7% of patients, respectively (91).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites [91] Chiodini, 2007, Subclinical hypercortisolism among outpatients referred for “osteoporosis.”, Ann Intern Med source
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies suggest that SH may be more frequent in patients with diabetes and osteoporosis, thus explaining the increased fracture risk.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A subsequent study of 10 subjects found after recovery from SH an improvement of blood pressure, metabolic control of diabetes, and dyslipidemia in 83, 22, and 67% of cases, respectively, whereas in 12 conservatively treated subjects, hypertension, diabetes, and obesity worsened in 17, 25, and 17% of cases, respectively (96).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [96] Tsuiki, 2008, Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome., Endocr J source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These data were confirmed in a similar controlled study on 294 diabetic inpatients in whom a 10.8% prevalence of SH was found, with pituitary, adrenal, and undefined/ectopic origin accounting for 1.4, 7.2, and 2.2%, respectively (83).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites [83] Chiodini, 2005, Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients., Eur J Endocrinol source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is possible to hypothesize that some patients classified as not having SH had, in fact, a mild degree of cortisol hypersecretion, suggesting that the diagnosis of SH had not been sensitive enough.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study clearly suffers from the limits of the small sample and of its retrospective and nonrandomized design.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, in reducing the cutoff of the screening test and therefore increasing its sensitivity, the adrenal cause of SH became more frequent than the pituitary cause.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In a cross-sectional study on 90 obese diabetic patients with poor metabolic control, Leibowitz et al. (63) found a 3.3% prevalence of SH due to an adrenal adenoma in one patient and a pituitary adenoma in two patients using 1-mg DST above 5.1 g/dl (140 nmol/liter) as a screening test.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites [63] Leibowitz, 1996, Pre-clinical Cushing's syndrome: an unexpected frequent cause of poor glycaemic control in obese diabetic patients., Clin Endocrinol (Oxf) source
Strength:plain· not yet calibratedn = 2Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Overall in this study, the prevalence of SH could be estimated to be almost 5.5%, with a pituitary and adrenal origin of 1.5 and 4.0%, respectively.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Prevalence of SH and of Its Different Causes
What the sources say
- Not checked yetcites [82] Catargi, 2003, Occult Cushing's syndrome in type-2 diabetes., J Clin Endocrinol Metab source
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Indeed, somatostatin analogs have been used to control food-dependent cortisol hypersecretion due to the presence of aberrant glucose-dependent insulinotropic peptide receptors (100, 101); propranolol has been proposed in patients with adrenal hypercortisolism (102) and leuprolide acetate in LH-dependent Cushing's syndrome (103).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
What the sources say
- Not checked yetcites [100] Libé, 2010, Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome., Eur J Endocrinol source
- Not checked yetcites [101] de Herder, 1996, Food-dependent Cushing's syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells., J Clin Endocrinol Metab
- Not checked yetcites [102] Lacroix, 1997, Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome., N Engl J Med source
- Not checked yetcites [103] Lacroix, 1999, Leuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome., N Engl J Med source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“However, to date, the small sample size of the available studies and the lack of a large prospective randomized trial could not allow us to draw any firm conclusion about this point.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Therapy of SH
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The difficulties in defining a protocol are related to the variability of cortisol secretion in these patients (3,22) because even a 2-yr follow-up may be too short to ascertain the presence of SH (79).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Follow-up of patients with SH
What the sources say
- Not checked yetcites [3] Grumbach, 2003, Management of the clinically inapparent adrenal masses (“incidentaloma”)., Ann Intern Med source
- Not checked yetcites [22] Terzolo, 2005, Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma., Eur J Endocrinol source
- Not checked yetcites [79] Donadio, 2009, Role of adrenal gland scintigraphy in patients with incidentally discovered adrenal mass and subclinical hypercortisolism., J Endocrinol Invest source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“These uncertainties, in turn, bring into question the real clinical importance of SH itself and the need of a surgical treatment in these patients instead of the optimization of medical therapy (61).”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Conclusions
What the sources say
- Not checked yetcites [61] Chiodini, 2010, Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism., J Clin Endocrinol Metab source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Moreover, it must be considered that the optimization of the medical therapy is not completely free of adverse events and that adrenal surgery is becoming increasingly safer by endoscopic procedures.”
§ Diagnosis and Treatment of Subclinical Hypercortisolism > Conclusions
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A chronic mild cortisol secretion abnormality may be associated with classic metabolic and cardiovascular complications of hypercortisolism (, -).”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
The osteoporosis studies are said to use the same DST dose, but Table 3 lists different doses
MinorThe text says the subsequent study used the same screening test as the 3-mg DST study. Table 3 lists a 1-mg DST for the subsequent Chiodini study.
“In assessing the HPA axis by 3-mg DST with a sensitive cutoff, a 3.8% prevalence of SH was found; all cases were of adrenal origin (90).A subsequent study from our group on more than 200 patients using the same screening test showed that SH was present in 4.8% of patients with osteoporosis”
“| Chiodini, 2007 (91) | Osteoporotics (147) | 1-mg DST | 1.8 g/dl | 4.8 | 85.4 | 14.6 | 0 |”
Study 97 is cited as showing both a positive surgical effect and no difference
MinorThe paper includes study 97 among studies showing a clear positive effect of surgery, but elsewhere says that study found no difference between surgical and conservative treatment.
“Importantly, studies using similar criteria were able to show a clear positive effect of surgery on the metabolic consequences of SH (18,54,61,93,96,97).”
“At variance with all the above-mentioned studies, a recent retrospective study found no difference in hypertension, diabetes, and obesity between five and eight SH patients surgically and conservatively treated, respectively (97).”
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 4×
“Second, the reliability of almost all markers of HPA axis activity, particularly ACTH and 24-h urinary free cortisol (UFC), is low (3, 14, 23), and several comorbidities (i.”
BackgroundInfluentialDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
Management of the clinically inapparent adrenal mass ("incidentaloma")
Grumbach, M. M., Biller, B. M. K., Braunstein, G. D., Campbell, K. K., Carney, J. A., Godley, P. A., Harris, E. L., Lee, J. K. T., Oertel, Y. C., Posner, M. C., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-5-200303040-00013 · Cited by 945 · cited 5×
“nomas smaller than 3 cm (3), two studies suggested that in”
BackgroundInfluentialA Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 907
The Diagnosis and Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States
Newell-Price, J., Trainer, P., Besser, M., & Grossman, A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0346 · Cited by 833
Prevalence of adrenal incidentaloma in a contemporary computerized tomography series
Bovio, S., Cataldi, A., Reimondo, G., Sperone, P., Novello, S., Berruti, A., Borasio, P., Fava, C., Dogliotti, L., Scagliotti, G. V., et al. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344099 · Cited by 712
Prevalence and natural history of adrenal incidentalomas
Barzon, L., Sonino, N., Fallo, F., Palu, G., & Boscaro, M. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490273 · Cited by 642
Zeiger, M. A., Thompson, G. B., Duh, Q.-Y., Hamrahian, A. H., Angelos, P., Elaraj, D., Fishman, E., Kharlip, J., Zeiger, M. A., Thompson, G. B., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.s1.1 · Cited by 499
Rossi, R., Tauchmanovà, L., Luciano, A., Martino, M. D., Battista, C., Viscovo, L. D., Nuzzo, V., & Lombardi, G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6515 · Cited by 416
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Tauchmanovà, L., Rossi, R., Biondi, B., Pulcrano, M., Nuzzo, V., Palmieri, E.-A., Fazio, S., & Lombardi, G. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011766 · Cited by 400
Incidentally discovered adrenal tumors: an institutional perspective.
Mf, H., Cs, G., van Heerden, J. A., Sheedy, P. F., & Dm, I. (1991) · PubMed · Cited by 356
Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome
Lacroix, A., N’Diaye, N., Tremblay, J., & Hamet, P. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.1.0420 · Cited by 350
Nonfunctioning adrenal masses: incidental discovery on computed tomography
Glazer, H., Weyman, P., Sagel, S., Levitt, R., & McClennan, B. (1982) · American Journal of Roentgenology · doi:10.2214/ajr.139.1.81 · Cited by 347
Reincke, M., Nieke, J., Krestin, G. P., Saeger, W., Allolio, B., & Winkelmann, W. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517373 · Cited by 346
(2002) · PubMed · Cited by 326
Adrenal incidentaloma: a new cause of the metabolic syndrome?
Terzolo, M., Pia, A., Alì, A., Osella, G., Reimondo, G., Bovio, S., Daffara, F., Procopio, M., Paccotti, P., Borretta, G., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8277 · Cited by 322
Occult Cushing’s syndrome in type-2 diabetes
Catargi, B., Rigalleau, V., Poussin, A., Ronci-Chaix, N., Bex, V., Vergnot, V., Gin, H., Roger, P., & Tabarin, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030254 · Cited by 287
Subclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1
Barzon, L., Scaroni, C. M., Sonino, N., Fallo, F., Paoletta, A., & Boscaro, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5444 · Cited by 255
Clinical Features Associated with Glucocorticoid Receptor Polymorphisms: An Overview
Manenschijn, L., van den Akker, E. L. T., Lamberts, S. W. J., & van Rossum, E. F. C. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05013.x · Cited by 249
Toniato, A., Merante-Boschin, I., Opocher, G., Pelizzo, M. R., Schiavi, F., & Ballotta, E. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e31819a47d2 · Cited by 245 · cited 1×
“Nonetheless, as observed by the authors, these data suggest that surgical treatment is more beneficial than conservative treatment (57).”
BackgroundLeuprolide acetate therapy in luteinizing hormone-dependent Cushing's syndrome.
Lacroix, A., Hamet, P., & Boutin, J.-M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412104 · Cited by 244
Taylor, R. L., Machacek, D., & Singh, R. J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1511 · Cited by 218
Long-term follow-up study of patients with adrenal incidentalomas.
Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470489 · Cited by 215
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas)
Osella, G., Terzolo, M., Borretta, G., Magro, G., Alí, A., Piovesan, A., Paccotti, P., & Angeli, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989452 · Cited by 206
Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome.
Lacroix, A., Tremblay, J., Rousseau, G., Bouvier, M., & Hamet, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711133372004 · Cited by 204
Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198
Chiodini, I., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2387 · Cited by 191
Self-citationChiodini, I., Torlontano, M., Scillitani, A., Arosio, M., Bacci, S., Di Lembo, S., Epaminonda, P., Augello, G., Enrini, R., Ambrosi, B., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02045 · Cited by 190
Self-citationUpdated review on the benefits of weight loss
Vidal, J. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802215 · Cited by 188 · cited 1×
“The improvement or worsening of body weight should be defined by a greater than 5–10% decrease or increase, respectively (104).”
BackgroundHypercholesterolaemia and its management
Bhatnagar, D., Soran, H., & Durrington, P. N. (2008) · BMJ · doi:10.1136/bmj.a993 · Cited by 187
A physiologic approach to diagnosis of the Cushing syndrome.
Raff, H., & Findling, J. W. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00010 · Cited by 186 · cited 1×
“6 pmol/liter) after CRH excludes the presence of an ACTH-dependent SH (76).”
BackgroundLeibowitz, G., Tsur, A., Chayen, S. D., Salameh, M., Raz, I., Cerasi, E., & Gross, D. J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.737558.x · Cited by 180 · cited 2×
“levels (21, 43, 48, 49, 53, 60, 63), loss of cortisol secretion”
Subclinical Cushing’s syndrome in adrenal incidentalomas
Terzolo, M., Bovio, S., Reimondo, G., Pia, A., Osella, G., Borretta, G., & Angeli, A. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.01.008 · Cited by 179
Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans.
Liu, H., Bravata, D. M., Cabaccan, J., Raff, H., & Ryzen, E. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02395.x · Cited by 178
Chiodini, I., Morelli, V., Masserini, B., Salcuni, A. S., Eller-Vainicher, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Carnevale, V., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0468 · Cited by 168
Self-citationMarcus, R., Wong, M., Heath, H., & Stock, J. L. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0453 · Cited by 164
Development of overt Cushing’s syndrome in patients with adrenal incidentaloma
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460061 · Cited by 162
Subclinical hypercortisolism among outpatients referred for osteoporosis.
Chiodini, I., Mascia, M. L., Muscarella, S., Battista, C., Minisola, S., Arosio, M., Santini, S. A., Guglielmi, G., Carnevale, V., & Scillitani, A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00006 · Cited by 162
Self-citationMolitch, M. E. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.05.001 · Cited by 155
Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients
Kasperlik‐Załuska, A. A., Rosłonowska, E., Słowińska‐Srzednicka, J., Migdalska, B., Jeske, W., Makowska, A., & Snochowska, H. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1751.x · Cited by 155 · cited 4×
“Low serum ACTH levels are frequently found in AI patients (19, 21, 32, 36, 40, 43, 44, 48, 49, 56, 60, 61).”
BackgroundMethodInfluentialChidiac, R. M., & Aron, D. C. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70242-5 · Cited by 140
Abnormalities of endocrine function in patients with clinically silent adrenal masses.
Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320422 · Cited by 136 · cited 4×
“The determination of ACTH levels after CRH does not seem to add any advantage (1, 23, 34, 35, 37, 38, 46) to screening for SH.”
BackgroundInfluentialThe improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection
Midorikawa, S., Sanada, H., Hashimoto, S., Suzuki, T., & Watanabe, T. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01274.x · Cited by 134
Body Composition and Metabolic Features in Women with Adrenal Incidentaloma or Cushing's Syndrome
Garrapa, G., Pantanetti, P., Arnaldi, G., Mantero, F., & Faloia, E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8059 · Cited by 132
Nunes, M.-L., Vattaut, S., Corcuff, J.-B., Rault, A., Loiseau, H., Gatta, B., Valli, N., Letenneur, L., & Tabarin, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1542 · Cited by 129
Kidambi, S., Raff, H., & Findling, J. W. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0424 · Cited by 129
Exploration and management of adrenal incidentalomas.
Tabarin, A., Bardet, S., Bertherat, J. Y., Dupas, B., Chabre, O., Hamoir, E., Laurent, F., Tenenbaum, F., Cazalda, M., Lefèbvre, H., et al. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.09.003 · Cited by 129
Bülow, B., Ahrén, B., & the Swedish Research Council Study Group of Endocrine Abdominal Tumours (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01028.x · Cited by 120
Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications.
Tsagarakis, S., Vassiliadi, D., & Thalassinos, N. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03344133 · Cited by 113
Libé, R., Coste, J., Guignat, L., Tissier, F., Lefebvre, H., Barrande, G., Ajzenberg, C., Tauveron, I., Clauser, E., Dousset, B., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0195 · Cited by 111
Morelli, V., Masserini, B., Salcuni, A. S., Eller‐Vainicher, C., Savoca, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Iorio, L., et al. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03794.x · Cited by 107
de Herder, W. W., Hofland, L. J., Usdin, T. B., de Jong, F. H., Uitterlinden, P., van Koetsveld, P. M., Mezey, É., Bonner, T. I., Bonjer, H. J., & Lamberts, S. W. J. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784063 · Cited by 107
Masserini, B., Morelli, V., Bergamaschi, S., Ermetici, F., Eller-Vainicher, C., Barbieri, A. M., Maffini, M. A., Scillitani, A., Ambrosi, B., Beck-Peccoz, P., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0485 · Cited by 106
Self-citationBernini, G., Moretti, A., Iacconi, P., Miccoli, P., Nami, R., Lucani, B., & Salvetti, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480213 · Cited by 105
EMRAL, R., UYSAL, A. R., ASIK, M., GULLU, S., CORAPCIOGLU, D., TONYUKUK, V., & ERDOGAN, G. (2003) · Endocrine Journal · doi:10.1507/endocrj.50.399 · Cited by 104
Erbil, Y., Ademoğlu, E., Özbey, N., Barbaros, U., Yanık, B. T., Salmaslıoğlu, A., Bozbora, A., & Özarmağan, S. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0681-x · Cited by 102
TSUIKI, M., TANABE, A., TAKAGI, S., NARUSE, M., & TAKANO, K. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-177 · Cited by 97
Torlontano, M., Chiodini, I., Pileri, M., Guglielmi, G., Cammisa, M., Modoni, S., Carnevale, V., Trischitta, V., & Scillitani, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5856 · Cited by 91
Self-citationScreening of Cushing’s syndrome in adult patients with newly diagnosed diabetes mellitus
Reimondo, G., Pia, A., Allasino, B., Tassone, F., Bovio, S., Borretta, G., Angeli, A., & Terzolo, M. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02865.x · Cited by 89 · cited 2×
“15 g/dl 0 0 0 0 Reimondo, 2007 (85) Type 2 diabetics (100) 1-mg DST 3.”
BackgroundTerzolo, M., Bovio, S., Pia, A., Conton, P. A., Reimondo, G., Dall’Asta, C., Bemporad, D., Angeli, A., Opocher, G., Mannelli, M., et al. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01959 · Cited by 89
Management of incidentally discovered adrenal masses and risk of malignancy
Favia, G., Lumachi, F., Basso, S., & D'Amico, D. F. (2000) · Surgery · doi:10.1067/msy.2000.109965 · Cited by 87
The Diagnosis of Cushing's Syndrome
Boscaro, M., Barzon, L., & Sonino, N. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3045 · Cited by 84
“Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients
Mitchell, I. C., Auchus, R. J., Juneja, K., Chang, A. Y., Holt, S. A., Snyder, W. H., & Nwariaku, F. E. (2007) · Surgery · doi:10.1016/j.surg.2007.10.001 · Cited by 84
Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas.
Valli, N., Catargi, B., Ronci, N., Vergnot, V, Leccia, F., Ferriere, J., Chene, G., Grenier, N., Laurent, F., & Tabarin, A. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440401 · Cited by 83
Chiodini, I., Guglielmi, G., Battista, C., Carnevale, V., Torlontano, M., Cammisa, M., Trischitta, V., & Scillitani, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031413 · Cited by 82
Self-citationSereg, M., Szappanos, Á., Tőke, J., Karlinger, K., Feldman, K., Kaszper, É., Varga, I., Gláz, E., Rácz, K., & Tóth, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0707 · Cited by 81
Subclinical Cushing's syndrome.
Terzolo, M., Reimondo, G., Bovio, S., & Angeli, A. (2004) · Pituitary · doi:10.1007/s11102-005-4024-6 · Cited by 80
Valassi, E., Swearingen, B., Lee, H., Nachtigall, L. B., Donoho, D. A., Klibanski, A., & Biller, B. M. K. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1500 · Cited by 78
Tsagarakis, S., Roboti, C., Kokkoris, P., Vasiliou, V., Alevizaki, C., & Thalassinos, N. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00509.x · Cited by 75
Flecchla, D., Mazza, E., Carllni, M., Blatto, A., Ollvlerl, F., Serra:, G., Camannl, F., & Messlna, M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01852.x · Cited by 75
Eller-Vainicher, C., Morelli, V., Salcuni, A. S., Torlontano, M., Coletti, F., Iorio, L., Cuttitta, A., Ambrosio, A., Vicentini, L., Carnevale, V., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0775 · Cited by 75
Self-citationEller-Vainicher, C., Morelli, V., Salcuni, A. S., Battista, C., Torlontano, M., Coletti, F., Iorio, L., Cairoli, E., Beck-Peccoz, P., Arosio, M., et al. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0602 · Cited by 73 · cited 10×
“Low serum ACTH levels are frequently found in AI patients (19, 21, 32, 36, 40, 43, 44, 48, 49, 56, 60, 61).”
BackgroundMethodInfluentialBardet, S., Rohmer, V., Murat, A., Guillemot, C., Maréchaud, R., Chupin, M., Lecomte, P., Simon, D., Delemer, B., Schneebelli, S., et al. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.720541.x · Cited by 71 · cited 2×
“The determination of ACTH levels after CRH does not seem to add any advantage (1, 23, 34, 35, 37, 38, 46) to screening for SH.”
BackgroundChiodini, I., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Ermetici, F., Morelli, V., Salcuni, A. S., Carnevale, V., Urbano, F., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03310.x · Cited by 71
Self-citationReznik, Y., Lefebvre, H., Rohmer, V., Charbonnel, B., Tabarin, A., Rodien, P., Lecomte, P., Bardet, S., Coffin, C., & Mahoudeau, J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02048.x · Cited by 71
Bone loss rate in adrenal incidentalomas: a longitudinal study
Chiodini, I., Torlontano, M., Carnevale, V., Guglielmi, G., Cammisa, M., Trischitta, V., & Scillitani, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8022 · Cited by 69
Self-citationIs there value in routine screening for Cushing’s syndrome in patients with diabetes?
Mullan, K., Black, N., Thiraviaraj, A., Bell, P. M., Burgess, C., Hunter, S. J., McCance, D. R., Leslie, H., Sheridan, B., & Atkinson, A. B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2453 · Cited by 65
A-I-D-S: the new endocrine epidemic.
Griffing, G. T. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989451 · Cited by 65
Role of glucocorticoid receptor polymorphism in adrenal incidentalomas
Morelli, V., Donadio, F., Eller-Vainicher, C., Cirello, V., Olgiati, L., Savoca, C., Cairoli, E., Salcuni, A. S., Beck‐Peccoz, P., & Chiodini, I. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02330.x · Cited by 63
Self-citationChiodini, I., Tauchmanovà, L., Torlontano, M., Battista, C., Guglielmi, G., Cammisa, M., Colao, A., Carnevale, V., Rossi, R., Di Lembo, S., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020399 · Cited by 63
Self-citationADA Standards of Medical Care in Diabetes
Moloo, J. (2016) · Journal watch · doi:10.1056/nejm-jw.na40627 · Cited by 62
Evaluation of hormonal function in a series of incidentally discovered adrenal masses.
Bondanelli, M., Campo, M., Trasforini, G., Ambrosio, M. R., Zatelli, M. C., Franceschetti, P., Valentini, A., Pansini, R., & Uberti, E. C. D. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90176-1 · Cited by 61
Stewart, P. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0633 · Cited by 61
Hadjidakis, D., Tsagarakis, S., Roboti, C., Sfakianakis, M., Iconomidou, V., Raptis, S. A., & Thalassinos, N. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01676.x · Cited by 60
Fagour, C., Bardet, S., Rohmer, V., Arimone, Y., Lecomte, P., Valli, N., & Tabarin, A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0299 · Cited by 58
Adrenal incidentalomas — a continuing management dilemma
Nawar, R., & Aron, D. C. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00951 · Cited by 56
Hwang, J.-Y., Lee, S. H., Kim, G. S., Koh, J.-M., Go, M. J., Kim, Y.-J., Kim, H.-C., Kim, T.-H., Hong, J. M., Park, E. K., et al. (2009) · Bone · doi:10.1016/j.bone.2009.07.080 · Cited by 55
Sereg, M., Tőke, J., Patócs, A., Varga, I., Igaz, P., Szücs, N., Horányi, J., Pusztai, P., Czirják, S., Gláz, E., et al. (2011) · Steroids · doi:10.1016/j.steroids.2010.08.007 · Cited by 53
van Rossum, E. F. C., Russcher, H., & Lamberts, S. W. J. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.10.009 · Cited by 53
The natural history of incidentally discovered adrenocortical adenomas: a retrospective evaluation.
Grossrubatscher, E., Vignati, F., Possa, M., & Loli, P. (2001) · Journal of Endocrinological Investigation · doi:10.1007/bf03343941 · Cited by 52
Bencsik, Z., Szabolcs, I., Kovács, Z., Ferencz, A., Vörös, A., Kaszás, I., Bor, K., Gönczi, J., Góth, M., Kovács, L., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626824 · Cited by 49
Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment.
Mazzuco, T. L., Bourdeau, I., & Lacroix, A. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32832b7043 · Cited by 48
Cushing’s syndrome in a clinic population with diabetes
Newsome, S., Chen, K., Hoang, J., Wilson, J. D., Potter, J. M., & Hickman, P. E. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2007.01434.x · Cited by 48 · cited 1×
“6 0 Newsome, 2008 (86) Type 2 diabetics (178) 1-mg DST 1.”
Szappanos, Á., Patócs, A., Tõke, J., Boyle, B., Sereg, M., Majnik, J., Borgulya, G., Varga, I., Likó, I., Rácz, K., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03528.x · Cited by 45
Subclinical hypercortisolism in hospitalized patients with type 2 diabetes mellitus
TANIGUCHI, T., HAMASAKI, A., & OKAMOTO, M. (2008) · Endocrine Journal · doi:10.1507/endocrj.k07e-045 · Cited by 42
Abdominal obesity increases overnight cortisol excretion.
Duclos, M., Corcuff, J.-B., Etcheverry, N., Rashedi, M., Tabarin, A., & Roger, P. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03343591 · Cited by 42
Rizza, R. A., Wahner, H. W., Spelsberg, T. C., Northcutt, R. C., & Moses, H. L. (1978) · PubMed · Cited by 40
Autonomy of cortisol secretion in clinically silent adrenal incidentaloma.
Tanabe, A., Naruse, M., Nishikawa, T., Yoshimoto, T., Shimizu, T., Seki, T., Takagi, S., Imaki, T., & Takano, K. (2001) · Hormone and Metabolic Research · doi:10.1055/s-2001-16234 · Cited by 36 · cited 3×
“circadian rhythm (22, 44, 48, 56, 60), altered cortisol and”
BackgroundKann, P., Laudes, M., Piepkorn, B., Heintz, A., & Beyer, J. (2001) · Clinical Rheumatology · doi:10.1007/s100670170099 · Cited by 34
[Detection of preclinical Cushing's syndrome in overweight type 2 diabetic patients].
Contreras, L. N., Cardoso, E., Lozano, M. P., Pozzo, J., Pagano, P., & Claus-Hermbeg, H. (2000) · PubMed · Cited by 28
Khanine, V., Fournier, J., Requeda, E., et al. (2000) · PubMed · Cited by 27
KATABAMI, T., OBI, R., SHIRAI, N., NAITO, S., & SAITO, N. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.463 · Cited by 24
Barzon, L., Fallo, F., Sonino, N., & Boscaro, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450223 · Cited by 21
Donadio, F., Morelli, V., Salcuni, A. S., Eller-Vainicher, C., Carletto, M., Castellani, M., Dellavedova, L., Scillitani, A., Beck-Peccoz, P., & Chiodini, I. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346511 · Cited by 13
Self-citation
Flagged first, then by citations
11 of the 122 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Measuring cortisol in serum, urine and saliva—Are our assays good enough?
El-Farhan, N., Rees, D. A., & Evans, C. (2017) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216687335 · Cited by 395
Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas
Debono, M., Bradburn, M., Bull, M., Harrison, B., Ross, R. J., & Newell-Price, J. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3007 · Cited by 269
Elhassan, Y. S., Alahdab, F., Prete, A., Delivanis, D. A., Khanna, A., Prokop, L., Murad, M. H., O'Reilly, M. W., Arlt, W., & Bancos, I. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3630 · Cited by 263
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors
Goh, G., Scholl, U. I., Healy, J. M., Choi, M., Prasad, M. L., Nelson-Williams, C. J., Kunstman, J. W., Korah, R. M., Suttorp, A., Dietrich, D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2956 · Cited by 263
Long-term follow-up in adrenal incidentalomas: an Italian multicenter study
Morelli, V., Reimondo, G., Giordano, R., Della Casa, S., Policola, C., Palmieri, S., Salcuni, A. S., Dolci, A., Mendola, M., Arosio, M., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3527 · Cited by 223
“Even if SH has been associated with the risk of major cardiovascular events (CVEs) (32), large studies focused on “hard” end-points, such as major CVEs, are lacking (11).”
Influential
Metadata
- Authors
- Chiodini, I.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Chiodini, Iacopo
- ORCID
- Chiodini, Iacopo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-05-01
- Volume
- 96
- Issue
- 5
- Pages
- 1223-1236
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2068496880
- Semantic Scholar
- b3e38e55547be819a98f080fc5eb59dd9144701d
- Cited by
- 279
- References
- 122
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 5 · 2023: 11 · 2022: 10 · 2021: 23 · 2020: 22 · 2019: 21 · 2018: 27 · 2017: 21 · 2016: 19 · 2015: 28 · 2014: 19 · 2013: 24 · 2012: 27
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- subclinical hypercortisolism, adrenal incidentaloma, cortisol excess, hypertension, diabetes mellitus, osteoporosis, obesity, adrenal surgery, metabolic recovery
- MeSH terms
- Adrenal Gland Neoplasms, Adult, Child, Cushing Syndrome, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review